A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are ...

Results from a separate trial that were released in 2022 showed patients taking a high dose of Lilly's Zepbound saw more than ...

Enter GetSimpli Oral Tirzepatide, a revolutionary product that promises to transform your approach to weight loss and metabolic health. Unlike traditional weight loss methods that often involve ...

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro added $3.5 billion, while obesity drug Zepbound ...

and tirzepatide, the active ingredient in Eli Lilly’s Zepbound. A recent study found that participants who used the GLP-1 medications without exercising experienced a significant decrease in ...